Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Authors: Zabana Yamile , Marín-Jiménez Ignacio , Rodríguez-Lago Iago , Vera Isabel , Martín-Arranz María Dolores , Guerra Iván , Gisbert Javier P. , Mesonero Francisco , Benítez Olga , Taxonera Carlos , Ponferrada-Díaz Ángel , Piqueras Marta , Lucendo Alfredo J. , Caballol Berta , Mañosa Míriam , Martínez-Montiel Pilar , Bosca-Watts Maia , Gordillo Jordi , Bujanda Luis , Manceñido Noemí , Martínez-Pérez Teresa , López Alicia , Rodríguez-Gutiérrez Cristina , García-López Santiago , Vega Pablo , Rivero Montserrat , Melcarne Luigi , Calvo Maria , Iborra Marisa , Barreiro de-Acosta Manuel , Sicilia Beatriz , Barrio Jesús , Pérez José Lázaro , Busquets David , Pérez-Martínez Isabel , Navarro-Llavat Mercè , Hernández Vicent , Argüelles-Arias Federico , Ramírez Esteso Fernando , Meijide Susana , Ramos Laura , Gomollón Fernando , Muñoz Fernando , Suris Gerard , de Zarate Jone Ortiz , Huguet José María , Llaó Jordina , García-Sepulcre Mariana Fe , Sierra Mónica , Durà Miguel , Estrecha Sandra , Fuentes Coronel Ana , Hinojosa Esther , Olivan Lorenzo , Iglesias Eva , Gutiérrez Ana , Varela Pilar , Rull Núria , Gilabert Pau , Hernández-Camba Alejandro , Brotons Alicia , Ginard Daniel , Sesé Eva , Carpio Daniel , Aceituno Montserrat , Cabriada José Luis , González-Lama Yago , Jiménez Laura , Chaparro María , López-San Román Antonio , Alba Cristina , Plaza-Santos Rocío , Mena Raquel , Tamarit-Sebastián Sonsoles , Ricart Elena , Calafat Margalida , Olivares Sonsoles , Navarro Pablo , Bertoletti Federico , Alonso-Galán Horacio , Pajares Ramón , Olcina Pablo , Manzano Pamela , Domènech Eugeni , Esteve Maria ,   on behalf of the ENEIDA registry of GETECCU
Published: January 2022

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.